Evidence map›Paper›PMID 40377959›Full record

ArticleChembiochem : a European journal of chemical biology2025

A Polyproline Type II Peptidomimetic Disrupts a Grb2 SH3C Domain Protein-Protein Interaction Implicated in Breast Cancer.

James Luccarelli, Philip C Simister, Andrew D Hamilton, Stephan M Feller, Sam Thompson

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

James LuccarelliChemistry Research Laboratory, Department of Chemistry, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK.
Philip C SimisterBiological Systems Architecture Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Andrew D HamiltonChemistry Research Laboratory, Department of Chemistry, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK.
Stephan M FellerBiological Systems Architecture Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Sam ThompsonChemistry Research Laboratory, Department of Chemistry, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK.ORCID https://orcid.org/0000-0001-6267-5693

Funding

Fostering Research Mentorship & Training during Psychiatry Residency SupplementR25MH094612 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI FAVA, MAURIZIO, GREENFIELD, SHELLY F. · 2011 to 2022
$2.3M
Cancer Research UKDFG 391498659NIMH NIH HHS R25 MH094612NIMH NIH HHS R25MH094612Oxford Cancer Research Centre Development FundRosetrees TrustUniversity of OxfordWessex Medical Research
6 · The paper itself

Abstract

Given the essential role of protein-protein interactions (PPIs) in cellular signaling pathways, their selective modulation is of great therapeutic interest. Mimicry of secondary structural protein elements has emerged as a promising strategy, with various scaffolds reproducing recognition surfaces of α-helical and β-strand/sheet proteins. A critical PPI, controlling cell growth and proliferation in breast and other cancers, occurs between growth factor receptor-bound protein 2 (Grb2) and a polyproline II (PPII) helix embedded in Gab2. Herein, the first example of a general approach for nonpeptidic mimicry of extended PPII helices is presented and it is demonstrated that the scaffold may be functionalized to recapitulate the binding characteristics of crucial hydrophobic and cationic Gab2 hot-spot side-chains. The rationally designed peptidomimetic binds Grb2 at the same position as Gab2 (protein-observed nuclear magnetic resonance (NMR)) with affinities comparable to the native peptide sequence (surface plasmon resonance (SPR)). With the addition of a new PPII minimalist scaffold, these studies further validate the use of diverse secondary structure peptidomimetics in disrupting therapeutically relevant PPIs.

Indexed as

Breast NeoplasmsGRB2 Adaptor ProteinPeptidesPeptidomimeticsFemaleHumansProtein Bindingsrc Homology DomainsGRB2 Adaptor ProteinGRB2 protein, humanPeptidesPeptidomimeticspolyprolineHer2mimicprotein–protein interactionssecondary structuresSH3 domains

Identifiers

PMID40377959
PMCPMC12278339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.